-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Aptevo Therapeutics Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q3 2016 to Q4 2024.
- Aptevo Therapeutics Inc. Earnings Per Share, Diluted for the quarter ending December 31, 2024 was -75.3 USD/shares, a 233% decline year-over-year.
- Aptevo Therapeutics Inc. Earnings Per Share, Diluted for the twelve months ending December 31, 2024 was -87.4 USD/shares, a 3666% decline year-over-year.
- Aptevo Therapeutics Inc. annual Earnings Per Share, Diluted for 2024 was -87.4 USD/shares, a 3671% decline from 2023.
- Aptevo Therapeutics Inc. annual Earnings Per Share, Diluted for 2023 was -2.32 USD/shares, a 248% decline from 2022.
- Aptevo Therapeutics Inc. annual Earnings Per Share, Diluted for 2022 was 1.57 USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)